13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001274403
Total reported value
$1.1B
$1.1B
9 檔
40.6%
At the close of Q3 2025, ARCH Venture Management, LLC disclosed equity holdings valued at approximately $1.1B, spread across 9 reported holdings.
ARCH Venture Management, LLC executed strategic sector rebalancing during Q3 2025, establishing 3 new positions while fully exiting 3 holdings and trimming 0 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | RAPP | Rapport Therapeutics Inc | Stock-Other | 22.49% | -3.11% | — | |
| 2 | BEAM | Beam Therapeutics Inc | Stock-Other | 22.38% | -1.82% | — | |
| 3 | MAZE | Maze Therapeutics Inc | Stock-Other | 21.70% | -6.98% | — | |
| 4 | VIR | Vir Biotechnology Inc | Stock-Other | 14.98% | -5.33% | — | |
| 5 | LYEL | Lyell Immunopharma Inc | Stock-Other | 9.10% | -5.48% | +51.54% | |
| 6 | ERAS | Erasca Inc | Stock-Other | 4.89% | -5.14% | — | |
| 7 | GOSS | Gossamer Bio Inc | Stock-Other | 4.30% | -0.27% | — | |
| 8 | QTTB | Q32 Bio Inc | Stock-Other | 0.13% | -0.30% | EXIT | |
| 9 | CERO | Cero Therapeutics Holdings I | Stock-Other | 0.02% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | RAPP | Rapport Therapeutics Inc | +4.3% | — | Unchanged |
| 2 | GOSS | Gossamer Bio Inc | 0% | — | Unchanged |
| 3 | QTTB | Q32 Bio Inc | -0.1% | — | Unchanged |
| 4 | MAZE | Maze Therapeutics Inc | -0.3% | — | Unchanged |
| 5 | ERAS | Erasca Inc | -2.5% | — | Unchanged |
| 6 | BEAM | Beam Therapeutics Inc | -20.6% | — | Unchanged |
| 7 | VIR | Vir Biotechnology Inc | — | NEW | New buy |
| 8 | LYEL | Lyell Immunopharma Inc | — | NEW | New buy |
| 9 | ✓ | Verve Therapeutics Inc | — | EXIT | Sold out |
| 10 | UNBX | Unity Biotechnology Inc | — | EXIT | Sold out |
| 11 | CERO | Cero Therapeutics Holdings I | — | NEW | New buy |
| 12 | ✓ | CERo Therapeutics Holdings Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, ARCH Venture Management, LLC reported a total U.S. public equity portfolio value of $1.1B across 9 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including RAPP, BEAM, MAZE) accounted for 40.6% of total reported equity market value during Q3 2025.
Top New Position Initiated
VIR
市值: $73.8M
Top Position Liquidated / Trimmed
VERVE THERAPEUTICS INC
前期市值: $9.1M
During Q3 2025, ARCH Venture Management, LLC's top holdings by market value included RAPP (22.5%)、BEAM (22.4%)、MAZE (21.7%). The largest single position, RAPP, represented 22.5% of total portfolio value.
In Q3 2025, ARCH Venture Management, LLC made 6 total portfolio adjustments, initiating 3 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 3 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.